SphK2 Over-expression Promotes Osteosarcoma Cell Growth

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 30

PMID 29285269

Citations 5

Authors

Dawei Xu

Hao Zhu

Chengniu Wang

Wei Zhao

Genxiang Liu

Guofeng Bao

Daoran Cui

Jianbo Fan

Fei Wang

Huricha Jin

Zhiming Cui

Affiliations

Soon will be listed here.

Abstract

It is needed to explore novel biological markers for early diagnosis and treatment of human osteosarcoma. Sphingosine kinase 2 (SphK2) expression and potential functions in osteosarcoma were studied. We demonstrate that SphK2 is over-expressed in multiple human osteosarcoma tissues and established human osteosarcoma cell lines. Silence of SphK2 by targeted-shRNAs inhibited osteosarcoma cell growth, and induced cell apoptosis. On the other hand, exogenous over-expression of SphK2 could further promote osteosarcoma cell growth. Notably, ("") targets the 3' UTR (untranslated region) of . Remarkably, forced-expression of silenced SphK2 and inhibited osteosarcoma cell growth. , SphK2 silence, by targeted-shRNA or , inhibited U2OS tumor growth in nude mice. These results suggest that SphK2 could be a novel and key oncotarget protein for OS cell progression.

Citing Articles

miR-153-3p Attenuates the Development of Gastric Cancer by Suppressing SphK2.

Jia Z, Tang X, Zhang X, Shen J, Sun Y, Qian L Biochem Genet. 2022; 60(5):1748-1761.

PMID: 35088224 DOI: 10.1007/s10528-021-10166-4.

Ceramide Metabolism Enzymes-Therapeutic Targets against Cancer.

Gomez-Larrauri A, Das Adhikari U, Aramburu-Nunez M, Custodia A, Ouro A Medicina (Kaunas). 2021; 57(7).

PMID: 34357010 PMC: 8303233. DOI: 10.3390/medicina57070729.

SphK2/S1P Promotes Metastasis of Triple-Negative Breast Cancer Through the PAK1/LIMK1/Cofilin1 Signaling Pathway.

Shi W, Ma D, Cao Y, Hu L, Liu S, Yan D Front Mol Biosci. 2021; 8:598218.

PMID: 33968977 PMC: 8100449. DOI: 10.3389/fmolb.2021.598218.

Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy.

Gupta P, Taiyab A, Hussain A, Alajmi M, Islam A, Hassan M Cancers (Basel). 2021; 13(8).

PMID: 33920887 PMC: 8071327. DOI: 10.3390/cancers13081898.

S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.

Shen Y, Zhao S, Wang S, Pan X, Zhang Y, Xu J EBioMedicine. 2018; 40:210-223.

PMID: 30587459 PMC: 6412077. DOI: 10.1016/j.ebiom.2018.12.038.

References

Kansara M, Teng M, Smyth M, Thomas D . Translational biology of osteosarcoma. Nat Rev Cancer. 2014; 14(11):722-35. DOI: 10.1038/nrc3838. View

Mullen T, Obeid L . Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. Anticancer Agents Med Chem. 2011; 12(4):340-63. DOI: 10.2174/187152012800228661. View

Kunkel G, Maceyka M, Milstien S, Spiegel S . Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013; 12(9):688-702. PMC: 3908769. DOI: 10.1038/nrd4099. View

Fan J, Ruan J, Liu W, Zhu L, Zhu X, Yi H . miR-135b expression downregulates Ppm1e to activate AMPK signaling and protect osteoblastic cells from dexamethasone. Oncotarget. 2016; 7(43):70613-70622. PMC: 5342578. DOI: 10.18632/oncotarget.12138. View

Denduluri S, Wang Z, Yan Z, Wang J, Wei Q, Mohammed M . Molecular pathogenesis and therapeutic strategies of human osteosarcoma. J Biomed Res. 2015; 30. DOI: 10.7555/JBR.29.20150075. View

Zhu Y, Min H, Fang J, Zhou F, Deng X, Zhang Y . Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma. Cancer Biol Ther. 2015; 16(4):602-9. PMC: 4622008. DOI: 10.1080/15384047.2015.1017155. View

Raje M, Knott K, Kharel Y, Bissel P, Lynch K, Santos W . Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors. Bioorg Med Chem. 2011; 20(1):183-94. PMC: 3748591. DOI: 10.1016/j.bmc.2011.11.011. View

Gong Y, Huang W, Li K, Liu Y, Cao G, Cao C . SC79 protects retinal pigment epithelium cells from UV radiation via activating Akt-Nrf2 signaling. Oncotarget. 2016; 7(37):60123-60132. PMC: 5312373. DOI: 10.18632/oncotarget.11164. View

Wu Q, Yang Z, An Y, Hu H, Yin J, Zhang P . MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis. 2014; 5:e1144. PMC: 3973221. DOI: 10.1038/cddis.2014.110. View

10.

Xun C, Chen M, Qi L, Tie-Ning Z, Peng X, Ning L . Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo. J Exp Clin Cancer Res. 2015; 34:94. PMC: 4559903. DOI: 10.1186/s13046-015-0205-y. View

11.

French K, Zhuang Y, Maines L, Gao P, Wang W, Beljanski V . Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010; 333(1):129-39. PMC: 2846016. DOI: 10.1124/jpet.109.163444. View

12.

He J, Hao Y, Wang X, Yang X, Shao J, Guo F . Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev. 2014; 15(15):5967-76. DOI: 10.7314/apjcp.2014.15.15.5967. View

13.

Shi W, Cui S, Song Z, Wang S, Sun S, Yu X . Overexpression of SphK2 contributes to ATRA resistance in colon cancer through rapid degradation of cytoplasmic RXRα by K48/K63-linked polyubiquitination. Oncotarget. 2017; 8(24):39605-39617. PMC: 5503636. DOI: 10.18632/oncotarget.17174. View

14.

Liu H, Toman R, Goparaju S, Maceyka M, Nava V, Sankala H . Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem. 2003; 278(41):40330-6. DOI: 10.1074/jbc.M304455200. View

15.

Yang J, Zhang W . New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013; 25(4):398-406. DOI: 10.1097/CCO.0b013e3283622c1b. View

16.

Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G . Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015; 113(2):275-81. PMC: 4506387. DOI: 10.1038/bjc.2015.201. View

17.

Salah Z, Arafeh R, Maximov V, Galasso M, Khawaled S, Abou-Sharieha S . miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells. Oncotarget. 2015; 6(7):4920-35. PMC: 4467124. DOI: 10.18632/oncotarget.3025. View

18.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

19.

Isakoff M, Bielack S, Meltzer P, Gorlick R . Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33(27):3029-35. PMC: 4979196. DOI: 10.1200/JCO.2014.59.4895. View

20.

Jonas S, Izaurralde E . Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 2015; 16(7):421-33. DOI: 10.1038/nrg3965. View